Abstract 5436: HH2853 is a selective small molecular dual inhibitor of EZH1/2 with potent anti-tumor activities

PRC2 EZH2型 组蛋白H3 生物 组蛋白甲基转移酶 癌症研究 甲基转移酶 甲基化 化学 细胞生物学 遗传学 基因
作者
Xuxing Chen,Qianqian Shen,Zhao Zhao,Yan-fen Fang,Jian Yang,Yijun Gao,Lei Liu,Yixiang Zhang,Yi Chen,Leping Li
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (12_Supplement): 5436-5436 被引量:4
标识
DOI:10.1158/1538-7445.am2022-5436
摘要

Abstract Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of lysine 27 on histone H3 (H3K27), and the histone methyltransferases EZH1/2 are the catalytic subunit of PRC2. Aberrant activation of EZH2 drives H3K27 methylation and plays a critical role in cancer initiation and progression. Meanwhile, loss-of-function mutation in the major components of SWI/SNF complex leads to a loss of its suppression ability against PRC2 and subsequently activates EZH2. Targeting EZH2 has been validated as a promising therapeutic strategy for cancer treatment, especially for those with EZH2 gain-of-function (GOF) mutations or alterations of SWI/SNF complex proteins that act as oncogenic drivers. Although when PRC2 was suppressed by EZH2 inhibition, the activity of EZH1 complementarily increased to replace the role of EZH2 and maintained the function of PRC2. In addition, EZH2 inhibition in hematopoietic stem cells of mice has been shown to facilitate the development of heterogeneous hematologic malignancies in an EZH1-dependent manner. As a result, dual inhibition of EZH1 and EZH2 may be more effective than EZH2 inhibition alone in suppressing PRC2 function, as well as overcoming the issues related to the development of secondary malignancies, which has been observed in the clinical development of EZH2 selective inhibitor. Thus, we discovered and developed HH2853,a dual inhibitor of EZH1/2. The potency and selectivity of HH2853 against EZH1/2 were assessed at biochemical and cellular levels, and its anti-tumor activities were evaluated in multiple tumor models in vitro and in vivo in comparison with FDA-approved EZH2 selective inhibitor tazemetostat. In addition, the pharmacokinetic (PK) profile of HH2853 was characterized. HH2853 inhibited the enzymatic activities of wild-type and mutant EZH2 with IC50 values of 2.21-5.36 nM, which was similar to that of tazemetostat. In addition, HH2853 inhibited EZH1 enzymatic activity with an IC50 of 9.26 nM, which was stronger than tazemetostat (IC50: 58.43 nM). In contrast, HH2853 up to 10 μM exhibited only marginal or minor inhibitory activity against 36 histone modification enzymes. At cellular level, HH2853 potently inhibited H3K27 mono-, di- and tri-methylation in multiple cancer cell lines with wild-type or mutant EZH2. In contrast, HH2853 up to 10 μM had no effect on the other types of methylation modifications on histone H3. Moreover, HH2853 potently inhibited the cell viability of multiple cancer cell lines with EZH2 GOF mutation or alterations in SWI/SNF complex, and exhibited superior anti-tumor efficacy in several tumor xenograft models than tazemetostat at a comparable dose level. Furthermore, HH2853 exhibited superior PK property than tazemetostat. Taken together, HH2853 is a selective EZH1/2 dual inhibitor with potent anti-tumor activities and favorable PK properties. HH2853 is currently in phase I clinical development. Citation Format: Xu-Xing Chen, Qian-Qian Shen, Zhao Zhao, Yan-Fen Fang, Jun-Yu Yang, Ying-Lei Gao, Lei Liu, Yixiang Zhang, Yi Chen, Leping Li. HH2853 is a selective small molecular dual inhibitor of EZH1/2 with potent anti-tumor activities [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5436.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
2秒前
3秒前
木棉发布了新的文献求助10
4秒前
5秒前
6秒前
Xdz发布了新的文献求助10
7秒前
科小银完成签到,获得积分10
8秒前
个性的紫菜应助龙龙采纳,获得20
9秒前
kf033发布了新的文献求助10
10秒前
11秒前
12秒前
Frank给跳跃仙人掌的求助进行了留言
13秒前
所所应助hhl采纳,获得10
14秒前
orixero应助是小袁呀采纳,获得10
15秒前
Kawhichan完成签到,获得积分10
15秒前
16秒前
科研小白完成签到,获得积分10
18秒前
木棉完成签到,获得积分10
18秒前
赘婿应助Xdz采纳,获得10
19秒前
852应助Disci采纳,获得10
20秒前
sunphor完成签到 ,获得积分10
21秒前
21秒前
Niki完成签到,获得积分10
23秒前
鲁棒的砰砰砰完成签到,获得积分10
23秒前
赘婿应助东方雨季采纳,获得10
25秒前
25秒前
牛牛完成签到,获得积分20
25秒前
27秒前
最佳完成签到 ,获得积分10
27秒前
27秒前
27秒前
图样图森破完成签到,获得积分10
29秒前
又见三皮发布了新的文献求助30
31秒前
Xdz发布了新的文献求助10
31秒前
无私诗云发布了新的文献求助10
32秒前
33秒前
ZhenpuWang完成签到,获得积分10
35秒前
35秒前
任性青烟完成签到,获得积分10
35秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Pharmacogenomics: Applications to Patient Care, Third Edition 800
A Dissection Guide & Atlas to the Rabbit 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3082501
求助须知:如何正确求助?哪些是违规求助? 2735655
关于积分的说明 7538441
捐赠科研通 2385263
什么是DOI,文献DOI怎么找? 1264761
科研通“疑难数据库(出版商)”最低求助积分说明 612786
版权声明 597665